2021
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
Malone R, Tisdall P, Fremont-Smith P, Liu Y, Huang X, White K, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker C, Wang G, Pottel J, Blair R, Roy C, Smith N, Hall J, Tomera K, Shapiro G, Mittermaier A, Kruse A, García-Sastre A, Roth B, Glasspool-Malone J, Ricke D. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Frontiers In Pharmacology 2021, 12: 633680. PMID: 33833683, PMCID: PMC8021898, DOI: 10.3389/fphar.2021.633680.Peer-Reviewed Original ResearchSARS-CoV-2 infectionCOVID-19 diseaseSARS-CoV-2Mast cell activationClinical COVID-19Acute viral diseaseMechanism of actionSymptoms of COVID-19Dose selectionClinical dataTreatment strategiesTreatment of COVID-19 diseaseHistamine releaseCell activationWell-characterized drugsCOVID-19 symptomsClinical COVID-19 diseaseOral formFamotidineMedical countermeasuresDiseaseInpatient treatmentCOVID-19InfectionSymptoms
2012
Corrigendum: Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
Laine L, Kivitz A, Bello A, Grahn A, Schiff M, Taha A. Corrigendum: Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. The American Journal Of Gastroenterology 2012, 107: 1272. DOI: 10.1038/ajg.2012.244.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply